asco 2014 meeting abstracts - home | memorial sloan kettering … · 2016-08-18 · 18. barr pm, li...

Compiled by the MSK Library on June 26, 2014 212-639-7439 [email protected]

Memorial Sloan Kettering Cancer Center ASCO Meeting Abstracts 2014

The abstracts selected for publication from this year’s ASCO Annual Meeting include 258 (12%) abstracts from Memorial Sloan Kettering out of a total of 2,100 abstracts. The top 7 MSK authors all published 10 or more abstracts: J. D. Wolchok (18), N. A. Rizvi (14), C. A. Hudis (13), M. G. Kris (12), R. J. Motzer (12), C. S. Sima (11), and J. Baselga (10) . The top three categories of articles (as determined by ASCO) were Gastrointestinal (Noncolorectal) Cancer (22), Lung Cancer-Non-Small Cell Metastatic (21), and Genitourinary (Prostate) Cancer (20). The abstracts included two on the historic IBM Watson Oncology application being implemented at MSK.

1. Abdel-Wahab OI, Diamond EL, Patel M, Holley VR, Cabrilo G, Rampal R, Hassaine L, Kosco K, Baselga J, Kurzrock R, Poole J, Vibat CRT, Erlander M, Janku F, Hyman DM. Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients. ASCO Meeting Abstracts. 2014;32(15_suppl):11012. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/11012. 2. Abou-Alfa GK, Cheng A-L, Meyer T, El-Khoueiry AB, Ikeda M, Chun HG, Faivre SJ, Furuse J, Knox JJ, Okusaka T, Ping J, Borgman-Hagey AE, Kelley RK. Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS4150. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4150. 3. Abou-Alfa GK, Yen C-J, Carrasquillo JA, Hsu C-H, Gansukh B, Ma J, Hollywood E, Wan PJ, Shao YY, Lin Z-Z, Frenette C, O'Neil BH, Schwartz LH, Ohtomo T, Tanaka T, Chen Y-C, Ukrainskyj S, Saltz L, Lee R-m, Cheng A-L. Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170). ASCO Meeting Abstracts. 2014;32(15_suppl):4100. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4100.

ASCO 2014 Meeting Abstracts

MSK Abstracts

Other

mailto:[email protected]


4. Aisner D, Sholl LM, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ, LCMC I Investigators. Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience. ASCO Meeting Abstracts. 2014;32(15_suppl):11030. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/11030. 5. Alken SP, Teo M, Bambury RM, Mohd Sharial MSN, O'Leary C, Jayaram A, Brett F, Connell LC, Farrell MA, Keohane C, Faul C, Moylan EJ, Power DG, Grogan W, Breathnach OS, Keane MM, O'Reilly S, Morris PG. Primary central nervous system lymphoma: The influence of radiotherapy on patient outcome in an unselected population. ASCO Meeting Abstracts. 2014;32(15_suppl):2044. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2044. 6. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DYC, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Hammers HJ. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2014;32(15_suppl):5010. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5010. 7. Antonia SJ, Brahmer JR, Gettinger SN, Chow LQM, Juergens RA, Shepherd FA, Laurie SA, Gerber DE, Goldman JW, Shen Y, Harbison C, Alaparthy S, Chen AC, Borghaei H, Rizvi NA. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):8113. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8113. 8. Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Chen AC, Ready N, Rizvi NA. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. ASCO Meeting Abstracts. 2014;32(15_suppl):8023. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8023. 9. Ariyan CE, Lefkowitz RA, Panageas K, Callahan MK, Misholy O, Bello D, Fisher C, Kotin A, Siegelbaum R, Coit DG, Wolchok JD, Brady MS. Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma. ASCO Meeting Abstracts. 2014;32(15_suppl):9078. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9078. 10. Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Beer TM. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).



ASCO Meeting Abstracts. 2014;32(15_suppl):5007. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5007. 11. Asija A, Sama AR, Casey J, Andrel Sendecki J, Lewis N, Lavu H, Winter JM, Brody JR, Mitchell EP, Yeo C, Prestipino A, Pillai MV. A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET). ASCO Meeting Abstracts. 2014;32(15_suppl):e15170. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15170. 12. Asmann YW, Wang C, Necela BM, Chen X, Kocher J-PA, Maurer MJ, Habermann TM, Slager SL, Feldman AL, Dogan A, Novak A, Cerhan JR, Perez EA, Thompson EA. An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data. ASCO Meeting Abstracts. 2014;32(15_suppl):e22171. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e22171. 13. Atkins MB, Kudchadkar RR, Sznol M, McDermott DF, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, Slingluff CL, Ernstoff MS, Fay JW, Friedlander PA, Gajewski T, Zarour HM, Rotem-Yehudar R, Sosman JA. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. ASCO Meeting Abstracts. 2014;32(15_suppl):9001. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9001. 14. Atkins MB, Voss MH, Plimack ER, Rini BI, Alter R, Dawson NA, Beck JT, Bhatt RS, Pappas KM, Wilson D, McClure T, Kumar R, Attie KM, Sherman ML, Pandya SS. A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts. ASCO Meeting Abstracts. 2014;32(15_suppl):4566. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4566. 15. Bajorin DF, Gomella LG, Sharma P, Plimack ER, O'Donnell PH, Hoffman-Censits JH, Flaig TW, Quinn DI, Campogan D, Haynes H, McCoy C, Maher J, DeVries T, Sheikh NA, Lerner SP. Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. ASCO Meeting Abstracts. 2014;32(15_suppl):4541. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4541. 16. Bakitas M, Tosteson T, Li Z, Lyons K, Hull J, Li Z, Dionne-Odom JN, Frost J, Hegel M, Azuero A, Ahles T, Rigas JR, Pipas JM, Dragnev KH. The ENABLE III randomized controlled trial of concurrent palliative oncology care. ASCO Meeting Abstracts. 2014;32(15_suppl):9512. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9512. 17. Bardia A, Modi S, Chavez-Mac Gregor M, Kittaneh M, Marino AJ, Matano A, Bhansali S, Hewes B, Cortes J. Phase Ib/II study of LEE011, everolimus, and



exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):535. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/535. 18. Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, Ul Haq M, Flowers C, Wagner-Johnston ND, Cheson BD, Horwitz SM, Miller TP, Fisher RI. U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). ASCO Meeting Abstracts. 2014;32(15_suppl):8523. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8523. 19. Bauer TM, Papadopoulos KP, Autio KA, Ott PA, Whiteside M, Oft M, Infante JR, Hodi FS, Wolchok JD. A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS3126. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3126. 20. Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D. Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN). ASCO Meeting Abstracts. 2014;32(15_suppl):4581. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4581. 21. Bellmunt J, Werner L, Leow JJ, Mullane SA, Riester M, Van Hummelen P, Rosenberg JE. Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):4511. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4511. 22. Bex A, de Bruijn R, Nijkamp J, Noe A, Horenblas S, Haanen JBAG. Volume of metastases and survival in patients with synchronous metastatic renal cell carcinoma (mRCC) of intermediate Memorial Sloan Kettering Cancer Center (MSKCC) prognosis. ASCO Meeting Abstracts. 2014;32(15_suppl):e15605. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15605. 23. Bharat A, Guenthart B, Rusch VW, Bains MS, Rizk NP. Role of PET scan in predicting response to neoadjuvant chemotherapy and long-term outcomes for stage II lung cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):7574. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7574. 24. Bitas C, Shoushtari AN, Bluth MJ, Bhuchar G, Hester RH, Romero J, Fitzpatrick L, Lefkowitz RA, Panageas K, Schwartz GK, Callahan MK, Postow MA, Wolchok JD, Chapman PB, Carvajal RD. The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma. ASCO Meeting Abstracts.



2014;32(15_suppl):9073. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9073. 25. Brahmer JR, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming PD, Topalian SL, Hodi FS, Sznol M, Harbison C, Kollia G, Gupta AK, Gettinger SN. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. ASCO Meeting Abstracts. 2014;32(15_suppl):8112. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8112. 26. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, Robbins PB, Vasselli J, Ibrahim RA, Antonia SJ. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstracts. 2014;32(15_suppl):8021. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8021. 27. Butowski NA, Colman H, De Groot JF, Omuro AMP, Nayak L, Cloughesy TF, Marimuthu A, Perry A, Phillips JJ, West B, Prados M, Nolop KB, Hsu HH, Ligon KL. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. ASCO Meeting Abstracts. 2014;32(15_suppl):2023. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2023. 28. Cadoo KA, Shah PD, Snyder Charen A, Bromberg J, Comen EA, D'Andrea G, Dang CT, Gilewski T, Gucalp A, Lake D, Seidman AD, Theodoulou M, Traina TA, Hudis CA, Norton L, Moynahan ME, Modi S, Dickler MN, Baselga J, Chandarlapaty S. A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):6601. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6601. 29. Callahan MK, Bendell JC, Chan E, Morse M, Pillai RN, Bono P, Jaeger D, Evans TRJ, Chau I, Calvo E, Le DT, Ott PA, Taylor MH, Sharma P, Antonia SJ, Sharkey B, Christensen O, Amin A. Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS3114. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3114. 30. Campbell AK, Martin ML, Arduino JM, Atkinson TM, Lundy JJ, Lungershausen J, Denis LJ, Liepa AM. Development of a patient-reported outcome (PRO) measure for assessing non-small cell lung cancer (NSCLC) symptoms in clinical trials: Interim report from the PRO Consortium's NSCLC Working Group (WG). ASCO Meeting Abstracts. 2014;32(15_suppl):e17620. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17620. 31. Carey LA, Barry WT, Pitcher B, Hoadley KA, Cheang MCU, Anders CK, Henry NL, Tolaney SM, Dang CT, Krop IE, Harris L, Berry DA, Perou CM, Winer EP, Hudis



CA, Alliance for Clinical Trials in Oncology. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). ASCO Meeting Abstracts. 2014;32(15_suppl):506. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/506. 32. Carvajal RD, Agulnik M, Ryan CW, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi HA-H, Elias AD, Read WL, Budd GT, Hirman J, Weiden P, Bennett CM, Livingston PO, Hansen D, Maki RG, Schwartz GK, Chugh R. Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. ASCO Meeting Abstracts. 2014;32(15_suppl):10520. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10520. 33. Cercek A, Aguilo A, Gluskin J, Chou JF, Reidy DL, Saltz L, Siegel C, Capanu M, Jarnagin WR, DeMatteo RP, Allen PJ, Kingham TP, Fong Y, D'Angelica MI, Kemeny NE. Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies. ASCO Meeting Abstracts. 2014;32(15_suppl):3623. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3623. 34. Choueiri TK, Escudier BJ, Powles T, Cella D, Ru QC, Scheffold C, Motzer RJ. Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS4601. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4601. 35. Choueiri TK, Hahn NM, Pal SK, Alva AS, Dreicer R, Starodub A, Sonpavde G, Hoffman-Censits JH, Picus J, Balar AV, Guancial EA, Regan MM, Jacobs C, Stewart PS, Rosenberg JE. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS4593. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4593. 36. Chow EJ, Chen Y, Armstrong GT, Border WL, Meacham LR, Mulrooney DA, Oeffinger KC, Sklar CA, Stovall M, Robison LL, Yasui Y. Individual risk prediction of major cardiovascular events after cancer: A Childhood Cancer Survivor Study report. ASCO Meeting Abstracts. 2014;32(15_suppl):10080. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10080. 37. Comen EA, Wojnarowicz P, Seshan VE, Blum B, Shah R, Coker C, Norton L, Benezra R. Gene-expression profiling to demonstrate select neutrophils from breast cancer patients versus healthy women as cytotoxic against breast cancer cells via novel chemokine-mediated mechanisms. ASCO Meeting Abstracts. 2014;32(15_suppl):11086. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/11086.



38. Copur MS, Ramaekers RC, Gonen M, Hadenfeldt R, Gulzow M, Benzel H, Scott J, Einspar S, Mickey M, Norvell M. Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT) activities in a community cancer center in rural Nebraska. ASCO Meeting Abstracts. 2014;32(15_suppl):6511. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6511. 39. Cuzick JM, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D, Moller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT. Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. ASCO Meeting Abstracts. 2014;32(15_suppl):5059. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5059. 40. Dang NH, Ogura M, Castaigne S, Fayad L, Jerkeman M, Radford JA, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Gine E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts. 2014;32(15_suppl):8529. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8529. 41. D'Angelo SP, Mahoney MR, Van Tine BA, Adkins D, Grosse Perdekamp MT, Condy MM, Hartley EW, Antonescu CR, Schwartz GK, Tap WD. Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). ASCO Meeting Abstracts. 2014;32(15_suppl):10568. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10568. 42. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin L-X, Carvajal RD, Dickson MA, Gounder MM, Keohan ML, Schwartz GK, Tap WD. PD-L1 expression and immune infiltrates in sarcoma. ASCO Meeting Abstracts. 2014;32(15_suppl):10522. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10522. 43. Danila DC, Szmulewitz RZ, Baron AD, Higano CS, Scher HI, Morris MJ, Gilbert H, Brunstein F, Lemahieu V, Kabbarah O, Fine BM, Maslyar DJ, Vaishampayan UN. A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). ASCO Meeting Abstracts. 2014;32(15_suppl):5024. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5024. 44. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at



higher cohort doses. ASCO Meeting Abstracts. 2014;32(15_suppl):8522. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8522. 45. De Wit R, Fizazi K, Jinga V, Efstathiou E, Fong PCC, Wirth M, Suzuki K, Moran S, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Borgstein NG, Saad F. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). ASCO Meeting Abstracts. 2014;32(15_suppl):5008. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5008. 46. Demetri GD, Rankin CJ, Benjamin RS, Borden EC, Ryan CW, Priebat DA, Tap WD, von Mehren M, Blackstein ME, Heinrich MC, Maki RG, Corless CL, Fletcher JA, Owzar K, Blanke CD. Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. ASCO Meeting Abstracts. 2014;32(15_suppl):10508. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10508. 47. DeMichele A, Dickson MA, Clark AS, Colameco C, Gallagher M, Gramlich K, Zafman K, Lewis D, Langer M, Vaughn DJ, Schwartz GK, O'Dwyer PJ. Characterization of isolated, uncomplicated neutropenia-related to the CDK4/6 inhibitor palbociclib. ASCO Meeting Abstracts. 2014;32(15_suppl):2547. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2547. 48. Diab A, McArthur HL, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Comen EA, Morris EA, Kotin A, Brogi E, Morrow M, Allison JP, Hudis CA, Norton L, Wolchok JD. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). ASCO Meeting Abstracts. 2014;32(15_suppl):1098. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1098. 49. Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Schwartz GK. Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. ASCO Meeting Abstracts. 2014;32(15_suppl):10527. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10527. 50. Dietz AC, Chen Y, Ness KK, Hagood JS, Chow EJ, Yasui Y, Stovall M, Neglia JP, Oeffinger KC, Mertens A, Robison LL, Armstrong GT, Mulrooney DA. Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). ASCO Meeting Abstracts. 2014;32(15_suppl):10022. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10022. 51. DiPersio JF, Erba HP, Larson RA, Luger SM, Mangan KF, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Zanna C, Sorensen JM. Phase I study of Debio1143 (AT406) in



combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). ASCO Meeting Abstracts. 2014;32(15_suppl):7029. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7029. 52. Dittamore R, Louw J, Krupa R, Danila DC, Arslan Z, Schreiber NA, Bales N, Marrinucci D, Scher HI. Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2014;32(15_suppl):e16018. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16018. 53. Drilon AE, Hellmann MD, Wang L, Cho EJ, Ladanyi M, Rizvi NA. Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers. ASCO Meeting Abstracts. 2014;32(15_suppl):8076. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8076. 54. Drilon AE, Wang L, Arcila ME, Cho EJ, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA. Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in "pan-negative" lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history. ASCO Meeting Abstracts. 2014;32(15_suppl):8029. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8029. 55. Dudenkov TM, Ingle JN, Buzdar A, Robson ME, Kubo M, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Fridley BL, Goetz MP, Northfelt DW, Perez EA, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM. Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):593. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/593. 56. Eaton A, Gonen M, Karanicolas PJ, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Jarnagin WR, Allen PJ. Health-related quality of life (HRQoL) following pancreatic resection in RCT of pasireotide. ASCO Meeting Abstracts. 2014;32(15_suppl):e15234. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15234. 57. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Karra Gurunath R, de Pril V, Suciu S, Testori A. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts. 2014;32(15_suppl):LBA9008. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA9008.



58. Eigl BJ, Pond GR, Milowsky MI, Kolinsky MP, Necchi A, Harshman LC, di Lorenzo G, Dorff TB, Lee RJ, Sonpavde G. Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study. ASCO Meeting Abstracts. 2014;32(15_suppl):e15616. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15616. 59. Elamin Y, Toomey S, Carr A, O'Byrne K, Rafee S, Gately K, Breathnach OS, Cuffe S, Grogan W, Morris PG, Hennessy B. The role of protein tyrosine phosphatase non-receptor 11 (PTPN11) mutations in lung squamous cell carcinoma (SQCC). ASCO Meeting Abstracts. 2014;32(15_suppl):e22174. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e22174. 60. Eng J, Hellmann MD, Woo K, Sima CS, Yu HA, Arcila ME, Ladanyi M, Kris MG, Drilon AE. Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas. ASCO Meeting Abstracts. 2014;32(15_suppl):8074. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8074. 61. Epstein AS, Crosbie C, Martin S, Egan B, Goring T, Koo D, Kumar C, Salvit C, Capanu M, Saltz L. Medical oncology patient readmissions: Are they preventable? ASCO Meeting Abstracts. 2014;32(15_suppl):6589. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6589. 62. Epstein AS, Zauderer MG, Gucalp A, Seidman AD, Caroline A, Fu J, Keesing J, Hsiao F, Megerian M, Eggebraaten T, DeLima R, Setnes M, Bach P, Kris MG. Next steps for IBM Watson Oncology: Scalability to additional malignancies. ASCO Meeting Abstracts. 2014;32(15_suppl):6618. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6618. 63. Eradat HA, Robak T, Delgado J, Schuh A, Pristupa AS, Omyla-Staszewska J, Barrientos JC, Farber CM, MacDonald D, Jacob A, Sharman JP, Loscertales J, Brown JR, Coiffier B, Ghia P, Zelenetz AD, Evans S, Jahn TM, Hallek MJ, Hillmen P. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS7127. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7127. 64. Escudier BJ, Rini BI, Motzer RJ, Tarazi JC, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA. Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. ASCO Meeting Abstracts. 2014;32(15_suppl):4528. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4528.



65. Evans FA, Liu J, Steingart R, Janjigian YY, Yu AF. An investigation of trastuzumab-induced cardiac dysfunction in adults with gastric and gastroesophageal junction cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):e15005. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15005. 66. Feldman DR, Jacobsen EP, Woo K, Steingart R, Fleisher M, Patil S, Carousso M, Laguerre S, Morales TD, Sheinfeld J, Motzer RJ, Bosl GJ, Oeffinger KC. Acute changes in endothelial function with cisplatin among germ cell tumor (GCT) patients (Pts). ASCO Meeting Abstracts. 2014;32(15_suppl):9587. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9587. 67. Feldman JL, Fox JJ, Martinez DF, Autio KA, Durack JC, Humm J, Schoder H, Gavane SC, Curtis KR, Balakirsky SM, Cohen RM, Scher HI, Larson SM, Morris MJ. Pathologic correlation of 18F-16{beta}-fluoro-5{alpha}-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2014;32(15_suppl):5016. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5016. 68. Fennell DA, Baas P, Kindler HL, Krug LM, Nowak A, Zauderer M, Gralla RJ, Keegan M, Horobin J. COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS7611. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7611. 69. Foo CK, St. John JA, Westesson O, Hahner NJ, Caulin AF, Skinner ME, Catalano JP, Lung K, Parikh UG, Wellde AS, Barry JK, Wellde GW, Rosell R, Weissman JS, Polkinghorn WR, Bivona TG, Giannikopoulos P. Clinical validation of a comprehensive cancer genomics analysis for lung cancer patients. ASCO Meeting Abstracts. 2014;32(15_suppl):e22122. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e22122. 70. Forero-Torres A, Moskowitz C, Advani RH, Shah BD, Kostic A, Albertson TM, Sandalic L, Zhao B, Fanale MA. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts. 2014;32(15_suppl):8505. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8505. 71. Foss FM, Pro B, Prince HM, Sokol L, Greenwood M, Caballero D, Horwitz SM, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). ASCO Meeting Abstracts. 2014;32(15_suppl):8563. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8563. 72. Fury MG, Xiao H, Baxi SS, Sherman EJ, Smith-Marrone S, Ho AL, Sima CS, Nwankwo OG, Haque S, Katabi N, Pfister DG. A phase II trial of temsirolimus plus low-



dose weekly carboplatin and paclitaxel for recurrent/metastatic HNSCC. ASCO Meeting Abstracts. 2014;32(15_suppl):6019. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6019. 73. Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, RISC Investigators. Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). ASCO Meeting Abstracts. 2014;32(15_suppl):4512. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4512. 74. Garcia-Manero G, Martinelli G, Zeidner JF, Avigan D, Anderson KC, Ribrag V, Moskowitz C, Zinzani PL, Wu D, Emancipator K, Dolled-Filhart M, Gause C, Brown H, Geschwindt RD, Iannone R, Rose S, Armand P. A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS3116. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3116. 75. Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, Goldman JW, Hui R, Soria J-C, Gangadhar TC, Sun J-M, Patnaik A, Gubens MA, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson ME, Gandhi L. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):8020. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8020. 76. Garrido Lopez P, Felip E, Delord J-P, Paz-Ares L, Grilley-Olson JE, Gordon MS, Barlesi F, Arkenau H-T, Lara P, Paik PK, Morgensztern D, Gadgeel SM, Reckamp KL, Bertino EM, Orlov S, Levchenko E, Delgado I, Trigo Perez JM, Moran T, Lassen UN. Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS8120. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8120. 77. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Rizvi NA. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO Meeting Abstracts. 2014;32(15_suppl):8024. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8024. 78. Ghia P, O'Brien SM, Hillmen P, Furman RR, Coutre SE, Sharman JP, Cheson BD, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Eradat HA, Lamanna N, Hallek MJ, Coiffier B, Pettitt A, Ye W, Jahn TM, Wagner LI. Health-related quality of life



(HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. ASCO Meeting Abstracts. 2014;32(15_suppl):7099. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7099. 79. Giannikopoulos P, St. John JA, Parker JS, Westesson O, Hahner NJ, Karachaliou N, Costa C, Caulin AF, Lozano MD, Perez-Gracia JL, Curioni Fontecedro A, Jantus-Lewintre E, Vergnenegre A, Gervais R, Bordoni R, Stahel RA, Cardona Zorrilla AF, Weissman JS, Polkinghorn WR, Bivona TG. Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers. ASCO Meeting Abstracts. 2014;32(15_suppl):8083. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8083. 80. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Mauro MJ, Michallet M, Paquette R, Simonsson B, Foreman A, Mohamed H, Subar M, Zyczynski TM. Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY). ASCO Meeting Abstracts. 2014;32(15_suppl):7050. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7050. 81. Goldfarb SB, Jackson T, Carter J, Dickler MN, Noy A. Sexual dysfunction in women with lymphoma: Prevalence and etiologies. ASCO Meeting Abstracts. 2014;32(15_suppl):e20594. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20594. 82. Gounder MM, Loong HHF, Nyquist-Schultz K, Baker S, Ustoyev Y, Tanner LR, Shacham S, McCauley D, Rashal T, Saint-Martin J-R, Shacham E, Friedlander S, Tamir S, Marshall T, Landesman Y, Kauffman M, Rebello S, Mirza MR, Schwartz GK, Razak ARA. A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas. ASCO Meeting Abstracts. 2014;32(15_suppl):10587. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10587. 83. Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA, Chemaitilly W, Pui C-H, Klosky J, Spunt SL, Metzger M, Navid F, Srivastava DK, Ness KK, Robison LL, Hudson MM. Alkylating agent exposure and sperm concentration in adult survivors of childhood cancer: A report from the St. Jude Lifetime (SJLIFE) Cohort Study. ASCO Meeting Abstracts. 2014;32(15_suppl):10010. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10010. 84. Grisham RN, Thapi D, Berman T, de Stanchina E, Zhou Q, Iasonos A, Iyer G, Aghajanian C, Spriggs DR. Effect of enzalutamide (Enza) on androgen receptor (AR) positive (+) ovarian cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):e16535. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16535. 85. Gucalp A, Krasne MD, Jakate KA, Drill EN, Wen YH, Akram M, Ho AY, Gupta GP, Brogi E, Hudis CA, Traina TA. CK14, FOXA1, and androgen receptor (AR)



expression in patients (pts) with triple-negative breast cancer (TNBC). ASCO Meeting Abstracts. 2014;32(15_suppl):1126. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1126. 86. Gucalp A, Morris PG, Zhou XK, Giri DD, Iyengar NM, Crew KD, Hershman DL, Garber JE, Nangia JR, Cook ED, Vornik L, Dunn BK, Heckman-Stoddard BM, Foster K, Brown P, Dannenberg A, Hudis CA, UT MD Anderson Early Phase Chemoprevention Consortium. A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS1615. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1615. 87. Halabi S, Kelly WK, Zhou H, Armstrong AJ, Quinn D, Fizazi K, Solomon NC, Tannock I, Petrylak DP, Morris MJ, Small EJ. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. ASCO Meeting Abstracts. 2014;32(15_suppl):5002. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5002. 88. Hamid O, Robert C, Ribas A, Wolchok JD, Hodi FS, Kefford R, Joshua AM, Hwu W-J, Gangadhar TC, Patnaik A, Hersey P, Weber JS, Joseph RW, Gergich K, Li X, Chun P, Ebbinghaus S, Kang SP, Daud A. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). ASCO Meeting Abstracts. 2014;32(15_suppl):3000. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3000. 89. Hamilton RJ, Li J, Naini V, Kheoh TS, De Porre P, Molina A, Leibowitz-Amit R, De Bono JS, Scher HI, Ryan CJ, Chi KN, Joshua AM. Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2014;32(15_suppl):e16045. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16045. 90. Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DYC, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Amin A. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2014;32(15_suppl):4504. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4504. 91. Harding JJ, Millis SZ, O'Reilly EM, Saltz L, Abou-Alfa GK, Venook AP, Mayer RJ, Choti MA, Cosgrove D. Multiplatform profiling of a fibrolamellar carcinoma cohort. ASCO Meeting Abstracts. 2014;32(15_suppl):e15125. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15125.



92. Hawkins DS, Anderson JR, Mascarenhas L, McCowage GB, Rodeberg DA, Wolden SL, Parham D, Million L, Donaldson SS, Hayes-Jordan AA, Brown KLB, Teot LA, Spunt SL, Meyer WH. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ASCO Meeting Abstracts. 2014;32(15_suppl):10004. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10004. 93. Hellmann MD, Anderson TA, Eng J, Sima CS, Kris MG, Moreira AL, Rekhtman N, Paik PK. Clinicopathologic characteristics and prognostic impact of MET receptor overexpression in patients with stage I-IIIA squamous cell lung carcinomas (SQCLCs). ASCO Meeting Abstracts. 2014;32(15_suppl):7570. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7570. 94. Hellmann MD, Borsu L, Zehir A, Cheng DT, Zha Z, Siegel B, Rohrer RW, Robson ME, Arnold AG, Harlan Fleischut M, Cavatore M, Gaskell AA, Gawel C, Robertson A, Viale A, Rusch VW, Krug LM, Ladanyi M, Zauderer MG. Prevalence of germline BAP1 mutations in patients with malignant mesothelioma (MM). ASCO Meeting Abstracts. 2014;32(15_suppl):e18542. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e18542. 95. Henderson TO, Moskowitz CS, Onel K, Bradbury AR, Friedman DN, Chou JF, Bhatia S, Strong LC, Neglia JP, Stovall M, Leisenring WM, Robison LL, Armstrong GT, Diller L, Oeffinger KC. Breast cancer in childhood cancer survivors not treated with chest-directed radiation in the Childhood Cancer Survivor Study (CCSS). ASCO Meeting Abstracts. 2014;32(15_suppl):10009. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10009. 96. Hertz DL, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey F, Patel JN, Carducci MA, Kelley MJ, Stadler WM, Mohamed MK, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). ASCO Meeting Abstracts. 2014;32(15_suppl):9612. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9612. 97. Ho AL, Sherman EJ, Fury MG, Baxi SS, Haque S, Sima CS, Antonescu CR, Katabi N, Pfister DG. Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma. ASCO Meeting Abstracts. 2014;32(15_suppl):6093. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6093. 98. Ho TH, Choueiri TK, D'Amelio A, Hsieh J, De Souza PL, Deen KC, Langmuir PB, Liu Y, Motzer RJ. The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ. ASCO



Meeting Abstracts. 2014;32(15_suppl):4583. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4583. 99. Hodi FS, Ribas A, Daud A, Hamid O, Robert C, Kefford R, Hwu W-J, Gangadhar TC, Joshua AM, Hersey P, Weber JS, Dronca RS, Perrone AM, Gammage L, Hille D, Xue D, Kang SP, Chun P, Ebbinghaus S, Wolchok JD. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts. 2014;32(15_suppl):3006. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3006. 100. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Leming PD, Lipson EJ, Taube JM, Anders R, Horak CE, Kollia G, Gupta AK, Sosman JA. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. ASCO Meeting Abstracts. 2014;32(15_suppl):9002. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9002. 101. Huh WK, Brady WE, Moore KN, Lankes HA, Monk BJ, Aghajanian C, Dizon DS, Armstrong DK, Thaker PH, Fracasso PM. A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS5617. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS5617. 102. Hyman DM, Blay J-Y, Chau I, Raje NS, Fernandez MEE, Wolf J, Sirzen F, Veronese ML, Mitchell L, Puzanov I, Baselga J. VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). ASCO Meeting Abstracts. 2014;32(15_suppl):2533. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2533. 103. Hyman DM, Rizvi NA, Natale RB, Armstrong DK, Birrer MJ, Recht LD, Dotan E, Gribbin MJ, McDevitt JT, Tavakkoli F, McCaffrey J, Sikorski R, Lai DW. A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):3012. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3012. 104. Ilson DH, Moughan J, Suntharalingam M, Dicker A, Kachnic LA, Konski AA, Chakravarthy B, Anker C, Thakrar HV, Horiba N, Kavadi V, Deutsch M, Raben A, Roof KS, Suh JH, Pollock J, Safran H, Crane CH. RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. ASCO Meeting Abstracts. 2014;32(15_suppl):4007. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4007.



105. Im S-A, Juric D, Baselga J, Kong A, Martin P, Lin C-C, Dees EC, Schellens JHM, De Braud FG, Delgado L, Zucchetto M, Tian X, Fernandez R, Morozov A, Dirix LY. A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):2519. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2519. 106. Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R, Issa I, Chakraborty A, Matano A, Zhao X, Parasuraman S, Cassier P. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. ASCO Meeting Abstracts. 2014;32(15_suppl):2528. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2528. 107. Isakoff SJ, He L, Mayer EL, Goss PE, Traina TA, Carey LA, Krag K, Liu MC, Rugo HS, Stearns V, Come SE, Ryan PD, Finkelstein DM, Hartman A-R, Garber JE, Timms K, Winer EP, Ellisen LW. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. ASCO Meeting Abstracts. 2014;32(15_suppl):1020. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1020. 108. Iyengar NM, Fornier MN, Sugarman S, Theodoulou M, Troso-Sandoval TA, D'Andrea G, Drullinsky P, Fasano J, Gajria D, Goldfarb SB, Comen EA, Lake D, Modi S, Traina TA, Chen M, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC). ASCO Meeting Abstracts. 2014;32(15_suppl):633. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/633. 109. Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri DD, Harbus M, Falcone DJ, Vahdat LT, Awad MI, Krasne MD, Subbaramaiah K, Morrow M, Hudis CA, Dannenberg A. Obesity and menopausal status as determinants of procarcinogenic breast inflammation. ASCO Meeting Abstracts. 2014;32(15_suppl):512. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/512. 110. Janelsins MC, Heckler CE, Mustian KM, Ontko M, Hopkins JO, Weiss M, Corso SW, Peppone LJ, Palesh O, Tejani MA, Mohile SG, Kamen CS, Peoples AR, Flannery MA, Ambrosone CB, Ahles T, Morrow GR. Prechemotherapy cognitive function in 362 breast cancer (BC) patients and 362 age-paired controls without cancer: A nationwide longitudinal trial conducted through the University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) Research Base (RB). ASCO Meeting Abstracts. 2014;32(15_suppl):9653. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9653.



111. Janjigian YY, Vakiani E, Imtiaz T, Huang X, Ilson DH, Rizk NP, Coit DG, Strong VE, de Stanchina E. Patient-derived xenografts as models for the identification of predictive biomarkers in esophagogastric cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):4059. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4059. 112. Johnson DB, Peng C, Abramson RG, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Ipilimumab in acral melanoma: A retrospective review. ASCO Meeting Abstracts. 2014;32(15_suppl):9056. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9056. 113. Johnson T, Xu C-f, Choueiri TK, Figlin RA, Sternberg CN, King KS, Xue Z, Stinnett S, Deen KC, Carpenter C, Spraggs CF, Bartlett-Pandite AN, Motzer RJ. Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC). ASCO Meeting Abstracts. 2014;32(15_suppl):4503. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4503. 114. Jones L, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, Tonorezos E, Soares-Miranda L, Sklar CA, Douglas PS, Robison LL, Oeffinger KC. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS). ASCO Meeting Abstracts. 2014;32(15_suppl):10023. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10023. 115. Joseph RW, Elassaiss-Schaap J, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Hwu W-J, Kefford R, Hersey P, Weber JS, Patnaik A, De Alwis DP, Perrone AM, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts. 2014;32(15_suppl):3015. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3015. 116. Joshi J, Mounier N, Xue X, Wang D, Ribera J-M, Wyen C, Dunleavy K, Little RF, Wilson WH, Noy A, Sparano JA, Barta SK. CNS involvement in patients with AIDS-related lymphomas. ASCO Meeting Abstracts. 2014;32(15_suppl):8570. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8570. 117. Joshua AM, Shore ND, Saad F, Chi KN, Olsson CA, Emmenegger U, Scholz MC, Berry WR, Mukherjee S, Winquist E, Haas NB, Hasabou N, Dmuchowski C, Perabo F, Hirmand M, Foley MA, Rathkopf DE, The Enzalutamide Expanded Access Study Investigators. Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. ASCO Meeting Abstracts. 2014;32(15_suppl):5051. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5051.



118. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, Weber JS, Dronca RS, Patnaik A, Zarour HM, Dolled-Filhart M, Lunceford J, Emancipator K, Ebbinghaus S, Kang SP, Hwu W-J. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts. 2014;32(15_suppl):3005. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3005. 119. Khasraw M, West L, Duan W, Mukaro V, Harvey S, Spokes R, Brandt C, Mitchell G, Prince K, Hayes TM, Baron-Hay SE, Woollett AM, Olesen IH, White K, Bowles S, Wong SF, Ashley DM, Patil S. Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS1135. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1135. 120. Kim D-W, Mehra R, Tan DS-W, Felip E, Chow LQM, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, Liu G, Santoro A, Geraldes M, Boral A, Yovine AJ, Shaw AT. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. ASCO Meeting Abstracts. 2014;32(15_suppl):8003. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8003. 121. King AA, Perkins SM, Seidel K, Di C, Leisenring WM, Krull KR, Sklar CA, Green DM, Armstrong GT, Zeltzer LK, Wells E, Stovall M, Ullrich N, Oeffinger KC, Robison LL, Packer R. Health and functional status of long-term adult medulloblastoma/PNet survivors: A report from the Childhood Cancer Survivor Study. ASCO Meeting Abstracts. 2014;32(15_suppl):9515. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9515. 122. Klotz A, Martin S, Atoria CL, Lipitz Snyderman AN, Groeger JS. The effect of observation units in cancer care on hospital admissions. ASCO Meeting Abstracts. 2014;32(15_suppl):e17633. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17633. 123. Koelwyn GJ, Lewis NC, Ellard S, Jones L, Gelinas JC, Rolf DJ, Melzer B, Thomas S, Douglas PS, Khouri M, Eves ND. Ventricular arterial coupling in early breast cancer patients following treatment with anthracycline-containing adjuvant chemotherapy. ASCO Meeting Abstracts. 2014;32(15_suppl):9591. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9591. 124. Kourelis T, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, Zeldensrust SR, Dogan A, Dispenzieri A. Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens. ASCO Meeting Abstracts. 2014;32(15_suppl):8605. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8605.



125. Kris MG, Hellmann MD, Naidoo J, Dunphy M, Sima CS, Downey RJ, Travis WD, Azzoli CG, Chaft JE. NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in 18F-FDG PET nonresponders. ASCO Meeting Abstracts. 2014;32(15_suppl):7515. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7515. 126. Land SR, Toll B, Warren GW, Brandon TH, Mitchell SA, Dresler CM, Gritz ER, Schnoll R, Sarna L, Moinpour C, Ostroff JS, Khuri FR, Buckner JC, Cummings KM, Herbst RS, Shields PG, Duffy S, Rigotti N, Prindiville SA, Abrams JS, National Cancer Institute American Association for Cancer Research Cancer Patient Tobacco Use Assessment Task Force. Standardizing measurement of tobacco use in cancer clinical trials. ASCO Meeting Abstracts. 2014;32(15_suppl):e17658. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17658. 127. Landry CA, Londono D, Devlin S, Jhanwar S, Giralt S, Landau HJ. Multiple copies of MLL as a commonly detected cytogenetic abnormality in newly diagnosed symptomatic multiple myeloma. ASCO Meeting Abstracts. 2014;32(15_suppl):e19585. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e19585. 128. LEE MK, Kim JY, Park J-H, Lee J, Kim D-i, Kang D, Oh M, An K-Y, Lee J-W, Chu S, Kim NK, Meyerhardt JA, Jones L, Jeon JY. Effect of 12-week home-based exercise program on fasting insulin in stage II-III colorectal cancer survivors: A randomized controlled trial. ASCO Meeting Abstracts. 2014;32(15_suppl):3588. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3588. 129. Lencioni R, Tak W-Y, Chen MH, Finn RS, Sherman M, Makris L, O'Neal M, Simonich W, Haemmerich D, Reed R, Borys N, Poon RTP, Abou-Alfa GK. Standardized radiofrequency ablation (sRFA) >= 45 minutes (m) plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of phase III HEAT study. ASCO Meeting Abstracts. 2014;32(15_suppl):e15143. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15143. 130. Levine DA, Sanders S, Chi D. Molecular profiling of serous ovarian carcinoma to identify extreme response phenotypes and diagnostic discrepancies. ASCO Meeting Abstracts. 2014;32(15_suppl):5532. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5532. 131. Lewis KD, Sekulic A, Hauschild A, Migden MR, Oro AE, LoRusso P, Rudin CM, Dirix L, Solomon JA, Hainsworth JD, Williams S, Hou J, Von Hoff DD. Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. ASCO Meeting Abstracts. 2014;32(15_suppl):9012. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9012.



132. Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM. Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC). ASCO Meeting Abstracts. 2014;32(15_suppl):4119. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4119. 133. Lilja H, Vickers AJ, Sjoberg D, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Stattin P. Improving the specificity of prostate cancer screening for early detection of lethal disease. ASCO Meeting Abstracts. 2014;32(15_suppl):5081. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5081. 134. Litvak AM, Woo K, Hayes SA, Sima CS, Huang J, Moreira AL, Tsukazan MTR, Riely GJ. Clinical characteristics and outcomes for patients with thymic carcinoma: Evaluation of Masaoka staging. ASCO Meeting Abstracts. 2014;32(15_suppl):7603. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7603. 135. Lowery MA, Lee A, Tobias E, Sung P, Bhanot U, Shakya R, Ludwig T, O'Reilly EM, Jasin M, Moynahan ME. Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):e15237. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15237. 136. Lunning MA, Ruan J, Nair S, Boruchov AM, Byrne R, Gerecitano JF, Hamlin PA, Inserra B, Leonard J, Lynch P, Matasar MJ, Moskowitz AJ, Moskowitz C, Myskowski PL, Nolan P, Palomba ML, Quefeld C, Straus DJ, Zelenetz AD, Horwitz SM. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results. ASCO Meeting Abstracts. 2014;32(15_suppl):8582. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8582. 137. Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S, Segal NH. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):3001. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3001. 138. Mahon F-X, Baccarani M, Mauro MJ, Hughes TP, Saglio G, Savona M, Szczudlo TK, Menssen HD, Keir CH, Walasek C, Hochhaus A. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS7124. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7124. 139. Martignetti J, Razak ARA, Chen Y, Gabrail NY, Gerecitano JF, Camacho C, Pereira E, Dottino PR, Shacham S, McCauley D, Rashal T, Saint-Martin J-R, Shacham E, Vincett D, Kauffman M, Mirza MR, Sorensen M. Preclinical and early clinical activity



of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa). ASCO Meeting Abstracts. 2014;32(15_suppl):5522. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5522. 140. Martin TG, Hsu K, Charpentier E, Vij R, Baz RC, Benson DM, Lendvai N. A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. ASCO Meeting Abstracts. 2014;32(15_suppl):8512. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8512. 141. Matsen CB, Villegas K, Eaton A, Stempel M, Manning A, Morrow M, Heerdt AS. Late axillary recurrence after negative SLNB. ASCO Meeting Abstracts. 2014;32(15_suppl):1033. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1033. 142. Matulonis U, Wulf GM, Birrer MJ, Westin SN, Quy P, Bell-McGuinn KM, Lasonde B, Whalen C, Aghajanian C, Solit DB, Mills GB, Cantley L, Winer EP. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). ASCO Meeting Abstracts. 2014;32(15_suppl):2510. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2510. 143. Mau-Soerensen M, Razak ARA, Shields AF, Gabrail NY, Gerecitano JF, Shacham S, Lassen UN, Rashal T, Cooksey J, Landesman Y, Pond G, Oza AM, Kauffman M, Siu LL, Bedard PL, Mahaseth H, Mirza MR, Mahipal A. A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):2537. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2537. 144. Mayer EL, Gropper AB, Tung NM, Higgins MJ, Traina TA, Barry WT, Winer EP, Burstein HJ. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS654. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS654. 145. Mayer EL, Vaz-Luis I, Richardson AL, Perou CM, Tung NM, Abramson VG, Anders CK, Forero-Torres A, Marcom PK, Miller K, Puhalla S, Rimawi MF, Stearns V, Traina TA, Barry WT, Jones JT, Timms K, Hartman A-R, Wolff AC, Winer EP. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)--Evaluating the homologous recombination deficiency (HRD) biomarker. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS1145. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1145.



146. McDermott DF, Infante JR, Voss MH, Motzer RJ, Haanen JBAG, Chowdhury S, Perini RF, Iannone R, Hodge R, Figueroa D, Suttle BB, Allred A, Rubin SD, Rini BI. A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS4604. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4604. 147. Meisel JL, Woo K, Sudarsan N, Eng J, Patil S, Jacobsen EP, Murali R, Motzer RJ, Bosl GJ, Aghajanian C, Feldman DR. Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience. ASCO Meeting Abstracts. 2014;32(15_suppl):5539. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5539. 148. Miller K, O'Neill AM, Dang CT, Northfelt DW, Gradishar WJ, Goldstein LJ, Mayer IA, Brufsky A, Bloom SH, Sparano JA, Tevaarwerk A, Fox KR, Hendricks CB, Balcueva EP, Sledge GW. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. ASCO Meeting Abstracts. 2014;32(15_suppl):500. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/500. 149. Miller VA, Chmielecki J, Hutchinson K, Frampton GM, Ali SM, Ross JS, Shi C, Pao W, Klimstra DS, Yelensky R, Lipson D, Stephens P. Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion. ASCO Meeting Abstracts. 2014;32(15_suppl):11029. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/11029. 150. Momtaz P, Gaskell AA, Merghoub T, Viale A, Chapman PB. Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAFV600Emutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi). ASCO Meeting Abstracts. 2014;32(15_suppl):9085. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9085. 151. Monk BJ, Grisham RN, Marth C, Banerjee SN, Hilpert F, Coleman RL, Pujade-Lauraine E, Pignata S, Mirza MR, Oza AM, del Campo JM, Oehler MK, James A, Christy-Bittel J, Barrett E, Boyd AP, Vergote I. The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS5618. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS5618. 152. Morikawa A, Jhaveri KL, Patil S, Chen M, McDonnell E, Neville DA, Mak FM, Gansukh B, John HL, Holodny A, Schoder H, Beal K, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment



response after WBRT sorafenib. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS2103. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS2103. 153. Morris MJ, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Lacuna KP, Scher HI. A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), {+/-} docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. ASCO Meeting Abstracts. 2014;32(15_suppl):5022. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5022. 154. Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, De Bono JS, Tombal BF, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Rathkopf DE. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. ASCO Meeting Abstracts. 2014;32(15_suppl):5054. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5054. 155. Moskowitz CS, Malhotra J, Chou JF, Wolden SL, Stovall M, Armstrong GT, Leisenring WM, Neglia JP, Robison LL, Oeffinger KC. Breast cancer following spinal radiotherapy for a childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). ASCO Meeting Abstracts. 2014;32(15_suppl):10082. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10082. 156. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Waxman I, Lambert A, Hammers HJ. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. ASCO Meeting Abstracts. 2014;32(15_suppl):5009. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5009. 157. Moynahan ME, Sung P, Asham M, Zamora S, Shah PD, Modi S, Lake D, D'Andrea G, Goldfarb SB, Chandarlapaty S, Hudis CA, Baselga J, Dickler MN, Patil S, Gaskell AA. Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K{alpha}-inhibitor plus letrozole (L) or exemestane (E). ASCO Meeting Abstracts. 2014;32(15_suppl):517. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/517. 158. Nabhan C, Byrtek M, Dawson KL, Zhou X, Ziemiecki R, Zelenetz AD, Friedberg JW, Cerhan JR, Flowers C. Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts). ASCO Meeting Abstracts. 2014;32(15_suppl):8550. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8550.



159. Naidoo J, Woo K, Sima CS, Rekhtman N, Thomas SB, Sarkaria IS, Rudin CM, Krug LM, Pietanza MC. Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung: Clinicopathologic features, treatment, and survival. ASCO Meeting Abstracts. 2014;32(15_suppl):e19046. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e19046. 160. Newton PK, Nieva JJ, Kuhn P, Norton L, Comen EA, Mason J, Venkatappa N, Jochelson MS. A Markov chain model of a longitudinal breast cancer data set. ASCO Meeting Abstracts. 2014;32(15_suppl):11040. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/11040. 161. Nghiemphu PL, Green S, Filka E, Lai A, Mellinghoff IK, Cloughesy TF. Pilot study of pulse high-dose lapatinib in combination with temozolomide (TMZ) and radiotherapy (RT) for upfront treatment of glioblastoma (GBM). ASCO Meeting Abstracts. 2014;32(15_suppl):2045. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2045. 162. Norden AD, Drappatz J, Phuphanich S, Reardon DA, Wong ET, Plotkin SR, Kaley TJ, Raizer JJ, Lesser GJ, Batchelor T, Lee EQ, Beroukhim R, Muzikansky A, Doherty LM, LaFrankie DC, Ruland S, Smith KH, Gerard M, McCluskey CS, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results. ASCO Meeting Abstracts. 2014;32(15_suppl):2027. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2027. 163. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Smith KH, Gaffey SC, McCluskey CS, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results. ASCO Meeting Abstracts. 2014;32(15_suppl):2053. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2053. 164. Nuciforo P, Thyparambil SP, Garrido-Castro AC, Peg V, Prudkin L, Jimenez J, Hoos WA, Burrows J, Hembrough TA, Perez-Garcia JM, Cortes J, Scaltriti M. Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy. ASCO Meeting Abstracts. 2014;32(15_suppl):649. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/649. 165. Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ, Lewis JS, Lyashchenko SK, Gudas JM. Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. ASCO Meeting Abstracts. 2014;32(15_suppl):e16057. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16057. 166. Omuro AMP, Kaley TJ, Pentsova E, DeAngelis LM, Urba WJ, Taylor MH, Anderson BD, Gorman G, McLean S, Karmali RA. Phase IB trial of



carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways. ASCO Meeting Abstracts. 2014;32(15_suppl):2071. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2071. 167. O'Reilly EM, Lowery MA, Segal MF, Smith SC, Moore MJ, Kindler HL, Golan T, Segal A, Salo-Mullen EE, Hollywood E, Epstein AS, Capanu M, Moynahan ME, Fusco A, Stadler ZK, Do RKG, Chen AP, Yu KH, Tang LH, Kelsen DP. Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). ASCO Meeting Abstracts. 2014;32(15_suppl):4023. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4023. 168. Owonikoko TK, Hussain A, Stadler WM, Smith DC, Sznol M, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli J, Cohen LJ. A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts. 2014;32(15_suppl):2558. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2558. 169. Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). ASCO Meeting Abstracts. 2014;32(15_suppl):3021. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3021. 170. Paik PK, Shen R, Ferry D, Soria J-C, Mathewson A, Kilgour E, Landers D, Frewer P, Brooks N, Andre F. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. ASCO Meeting Abstracts. 2014;32(15_suppl):8035. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8035. 171. Papadopoulos KP, Graham DM, Tolcher AW, Razak ARA, Patnaik A, Bedard PL, Rasco DW, Amaya A, Moore KN, Konner JA, Matei D, Martin LP, Adriaens L, Brownstein CM, Lowy I, Gao B, Kostic A, DiCioccio AT, Trail P, Siu LL. A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies. ASCO Meeting Abstracts. 2014;32(15_suppl):2522. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2522. 172. Park JH, Riviere I, Wang X, Bartido S, Sadelain M, Brentjens RJ. Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. ASCO Meeting



Abstracts. 2014;32(15_suppl):7020. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7020. 173. Park J-H, Yoon YJ, Lee CW, Lee J, Oh M, Chae J, Park H, Chu S, Kim SI, Kim NK, Jones L, Jeon JY. The effects of oncologists' physical activity recommendations and information packages on level of physical activity and the quality of life in cancer survivors. ASCO Meeting Abstracts. 2014;32(15_suppl):9629. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9629. 174. Park W, Mankal PK, O'Reilly EM. Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy. ASCO Meeting Abstracts. 2014;32(15_suppl):e15233. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15233. 175. Patel JN, Jiang C, Hertz DL, Mulkey F, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). ASCO Meeting Abstracts. 2014;32(15_suppl):e16061. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16061. 176. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Janne PA, Govindan R, Evans TL, Costa DB, Rosovsky RPG, Wakelee HA, Heist RS, Shaw AT, Temel JS, Shapiro MA, Muzikansky A, Lanuti M, Lynch TJ, Kris MG, Sequist LV. SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. ASCO Meeting Abstracts. 2014;32(15_suppl):7514. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7514. 177. Phillips AA, Fields P, Hermine O, Taylor G, Delioukina ML, Horwitz SM, Ramos JC, Meniane JCm, Barta SK, Dwyer KM, Kurman MR, Saunders A, Grebennik DO, Conlon K. Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS8622. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8622. 178. Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). ASCO Meeting Abstracts. 2014;32(15_suppl):LBA4. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA4. 179. Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchell EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB,



Braiteh FS, Lee F-C, Gribbin TE, Richards DA, Starodub A, Wegener WA, Goldenberg DM. Feasibility and results of a randomized phase Ib study of fractionated 90{Upsilon}-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. ASCO Meeting Abstracts. 2014;32(15_suppl):4026. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4026. 180. Pietanza MC, Krug LM, Varghese AM, Fleisher M, Teitcher JB, Holodny A, Sima CS, Litvak AM, Ng KK, Patel PR, Ibrahim F, Haughney-Siller A, Dulko D, Monger G, Albano M, Moran CM, Kris MG, Rudin CM. Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):7602. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7602. 181. Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Bunn PA, Khuri FR, Ramalingam SS. HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC). ASCO Meeting Abstracts. 2014;32(15_suppl):8060. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8060. 182. Pinder MC, Rizvi NA, Goldberg SB, Balmanoukian AS, Narwal R, Robbins PB, D'Angelo G, Blake-Haskins A, Karakunnel JJ, Antonia SJ. A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):e19137. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e19137. 183. Piperno-Neumann S, Kapiteijn E, Larkin JMG, Carvajal RD, Luke JJ, Seifert H, Roozen I, Zoubir M, Ramkumar T, Emery C, Derti A, Yerramilli-Rao P, Hodi FS, Schwartz GK. Landscape of genetic alterations in patients with metastatic uveal melanoma. ASCO Meeting Abstracts. 2014;32(15_suppl):9043. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9043. 184. Porkka K, Mauro MJ, Lipton JH, Mahon F-X, Strauss LC, Geese WJ, Kroog GS, Mustjoki S. An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS7119. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7119. 185. Postow MA, Kuk D, Bogatch K, Carvajal RD. Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma. ASCO Meeting Abstracts. 2014;32(15_suppl):9074. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9074.



186. Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD, Rini BI, Lin W, O'Keeffe B, Byrtek M, Lackner M, Spoerke JM, Ware JA, Zhu R, Motzer RJ, on behalf of the ROVER Study Group. A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). ASCO Meeting Abstracts. 2014;32(15_suppl):4525. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4525. 187. Qin L-X, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, Satagopan J, Begg CB, Levine DA. Blocking and randomization to improve molecular biomarker discovery. ASCO Meeting Abstracts. 2014;32(15_suppl):5573. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5573. 188. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh MN, Hauke RJ, Bandekar R, Maneval EC, De Boer C, Todd MB, Yu MK, Scher HI. ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment. ASCO Meeting Abstracts. 2014;32(15_suppl):5026. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5026. 189. Rathkopf DE, Carver BS, Chen Y, Morris MJ, Danila DC, Slovin SF, Autio KA, DeNunzio M, Sawyers CL, Scher HI. Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS5106. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS5106. 190. Reidy DL, Basturk O, Kriplani A, Abou-Alfa GK, Jarnagin WR, Allen PJ, Saltz L, Klimstra DS, Zhang L. MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy. ASCO Meeting Abstracts. 2014;32(15_suppl):e15169. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15169. 191. Renfro LA, Grothey A, Kerr DJ, Haller DG, Andre T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H-J, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints Group. Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP). ASCO Meeting Abstracts. 2014;32(15_suppl):3601. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3601. 192. Renfro LA, Loupakis F, Adams RA, Seymour MT, Schmoll H-J, Douillard J-Y, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Falcone A, Tebbutt NC, Hecht JR, Punt CJA, Goldberg RM, Saltz L, De Gramont A, Sargent DJ, Lenz H-J, ARCAD Clinical Trials Program. Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD



database. ASCO Meeting Abstracts. 2014;32(15_suppl):3537. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3537. 193. Reynolds KL, Juric D, Baselga J, Alsina M, Tabernero J, Bedard PL, Graham DM, Gonzalez-Angulo AM, Garrido-Laguna I, Sharma S, Lin C-C, Cohen EEW, Lee S-H, Zucchetto M, Tian X, Delgado L, Li J, Morozov A, Bang Y-J. A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):2517. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2517. 194. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu W-J, Gangadhar TC, Patnaik A, Joshua AM, Hersey P, Weber JS, Dronca RS, Zarour HM, Gergich K, Li X, Iannone R, Kang SP, Ebbinghaus S, Robert C. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstracts. 2014;32(15_suppl):LBA9000. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA9000. 195. Richards DA, Braiteh FS, Garcia AA, Denlinger CS, Conkling PR, Edenfield WJ, Anthony SP, Hellerstedt BA, Raju RN, Becerra C, Harb WA, Smith DA, McDonagh CF, Kawash K-L, Frye S, Moyo VM. A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):651. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/651. 196. Riely GJ, Eng J, Yu HA, Hsu M, Kris MG, Borsu L, Cavatore M, Yannes A, Brzostowski E, Casanova J, Viale A, Sima CS, Cheng DT, Ladanyi M. Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival. ASCO Meeting Abstracts. 2014;32(15_suppl):8033. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8033. 197. Rizvi NA, Chow LQM, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Gettinger SN. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstracts. 2014;32(15_suppl):8022. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8022. 198. Rizvi NA, Chow LQM, Dirix LY, Gettinger SN, Gordon MS, Kabbinavar FF, Von Pawel J, Soria J-C, Chappey C, Mokatrin A, Sandler A, Waterkamp D, Spigel DR. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS8123. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8123. 199. Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB, Balmanoukian AS, Goldman JW, Eder JP, Johnson E, Blumenschein GR, Gubens MA, Papadopoulos KP,



Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson ME, Hui R. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):8007. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8007. 200. Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel SB, D'Andrea AD, Garraway LA. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. ASCO Meeting Abstracts. 2014;32(15_suppl):4510. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4510. 201. Rugo HS, Yao JC, Hortobagyi GN, Pavel ME, Franz DN, Ravaud A, Taran T, Gallo J, Rouyrre N, Anak O, Motzer RJ. Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy. ASCO Meeting Abstracts. 2014;32(15_suppl):645. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/645. 202. Sadelain M, Condomines M, Zhao Z, Brentjens RJ, Riviere I. Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy. ASCO Meeting Abstracts. 2014;32(15_suppl):3022. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3022. 203. Sadot E, Basturk O, Klimstra DS, Gonen M, Kingham TP, D'Angelica MI, Fong Y, DeMatteo RP, Jarnagin WR, Allen PJ. Infiltrating neutrophils and malignant progression in intraductal papillary mucinous neoplasms (IPMN): An opportunity for identification of high-risk disease. ASCO Meeting Abstracts. 2014;32(15_suppl):4137. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4137. 204. Sahin IH, Geyer A, Kelly D, O'Reilly EM. Gemcitabine-related pneumonitis: Elucidation of risk factors. ASCO Meeting Abstracts. 2014;32(15_suppl):e15243. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15243. 205. Salles GA, Lamanna N, Amin BR, Boccia RV, Gabrail NY, Zaydan M-AA, Wong M, Adewoye AH, Ghia P. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS7123. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7123. 206. Santini D, Santoni M, De Giorgi U, Iacobelli S, Procopio G, Facchini G, Galli L, di Lorenzo G, Badalamenti G, Guida FM, Felici A, Marchetti P, Iacovelli R, Basso U, Adamo V, Longo F, Massari F, Carles J, Tonini G, Milella M. A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy. ASCO Meeting Abstracts.



2014;32(15_suppl):e15588. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15588. 207. Scher HI, Fizazi K, Lee C, Maclean D, Tejura B, Webb IJ, Borgstein NG, Dreicer R. Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial. ASCO Meeting Abstracts. 2014;32(15_suppl):5014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5014. 208. Schiller GJ, Tallman MS, Goldberg SL, Perl AE, Marie J-P, Martinelli G, Larson RA, Russell N, Trone D, Gammon G, Levis MJ, Cortes JE. Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia. ASCO Meeting Abstracts. 2014;32(15_suppl):7100. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7100. 209. Schindler K, Abraham R, Shah PD, Chandarlapaty S, Paik PK, Bell-McGuinn K, Bajorin DF, Mellinghoff IK, Younes A, Gounder MM, Fury MG, Busam KJ, Dickler MN, Lacouture ME. Clinical and histologic characterization of dermatologic adverse events from the pan-PI3K inhibitor buparlisib (BKM-120). ASCO Meeting Abstracts. 2014;32(15_suppl):e20639. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20639. 210. Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, Dummer R, Pehamberger H, Wolchok JD, Postow MA. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. ASCO Meeting Abstracts. 2014;32(15_suppl):9096. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9096. 211. Schwartzberg LS, Yardley DA, Elias AD, Patel MR, Gucalp A, Burris HA, Peterson AC, Hannah AL, Blaney ME, Gibbons J, Tudor IC, Steinberg JL, LoRusso P, Infante JR, Hudis CA, Traina TA. Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):545. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/545. 212. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J, Khleif S. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstracts. 2014;32(15_suppl):3002. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3002. 213. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R, Pishvaian MJ, Houot R, Bartlett N, Nghiem P, Kronenberg SA, Thall AD, Mugundu G, Huang B, Davis C. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. ASCO



Meeting Abstracts. 2014;32(15_suppl):3007. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3007. 214. Segal NH, Hodi FS, Sanborn RE, Gajewski T, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Kollia G, McDonald D, Kim SY, Sharfman WH. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS3115. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3115. 215. Serna-Tamayo C, Reyes-Habito CM, Belum VR, Lacouture ME. Concordance between oncologists and dermatologists in the assessment of dermatologic events: A preliminary study. ASCO Meeting Abstracts. 2014;32(15_suppl):e20683. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20683. 216. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW. ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. ASCO Meeting Abstracts. 2014;32(15_suppl):7015. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7015. 217. Shah PD, Modi S, Datko FM, Moynahan ME, Zamora S, D'Andrea G, Lake D, Goldfarb SB, Patil S, Singh S, Langley EJ, Kim PS, Covey AM, Caravella BA, Berger MF, Lacouture ME, Hudis CA, Baselga J, Chandarlapaty S, Dickler MN. Phase I trial of daily PI3K{alpha} inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2014;32(15_suppl):2605. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2605. 218. Shameem R, Lacouture ME, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials. ASCO Meeting Abstracts. 2014;32(15_suppl):e17585. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17585. 219. Shameem R, Lacouture ME, Wu S. Incidence and risk of stomatitis to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials. ASCO Meeting Abstracts. 2014;32(15_suppl):e17572. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17572. 220. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Hallek MJ, Coiffier B, O'Brien SM, Tausch E, Kreuzer KA, Jiang W, Jahn TM, Lazarov M, Stilgenbauer S. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.



ASCO Meeting Abstracts. 2014;32(15_suppl):7011. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7011. 221. Shoushtari AN, D'Angelo SP, Keohan ML, Dickson MA, Gounder MM, Abdullah AK, Erinjeri JP, Bluth MJ, Ustoyev Y, Condy MM, Streicher H, Takebe N, DeMatteo RP, Schwartz GK, Tap WD, Carvajal RD. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas. ASCO Meeting Abstracts. 2014;32(15_suppl):10521. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10521. 222. Shoushtari AN, Qin L-X, Kuk D, Magnan HD, Modak S, Wolden SL, Cho EJ, Pallos V, Grubman O, Viny AD, Carvajal RD, Chi P, D'Angelo SP, Dickson MA, Keohan ML, Tap WD, La Quaglia MP, Gounder MM. Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT). ASCO Meeting Abstracts. 2014;32(15_suppl):10582. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10582. 223. Snyder Charen A, Makarov V, Merghoub T, Walsh L, Yuan J, Miller M, Kannan K, Postow MA, Elipenahli C, Liu C, Wolchok JD, Chan TA. The neoantigen landscape underlying clinical response to ipilimumab. ASCO Meeting Abstracts. 2014;32(15_suppl):3003. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3003. 224. Sommeijer DW, Shi Q, Saad ED, Coart E, Buyse ME, Burzykowski T, Meyers JP, Maughan T, Adams RA, Seymour MT, Saltz L, Goldberg RM, Douillard J-Y, Schmoll H-J, Punt CJA, Tournigand C, Chibaudel B, De Gramont A, Sargent DJ, Zalcberg JR, for the ARCAD group. Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts. ASCO Meeting Abstracts. 2014;32(15_suppl):3538. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3538. 225. Sonpavde G, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Wong Y-N, Sridhar SS, Ko Y-J, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. ASCO Meeting Abstracts. 2014;32(15_suppl):4514. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4514. 226. Sosman JA, Kittaneh M, Lolkema MPJK, Postow MA, Schwartz G, Franklin C, Matano A, Bhansali S, Parasuraman S, Kim K. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. ASCO Meeting Abstracts. 2014;32(15_suppl):9009. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9009.



227. Spigel DR, Spira AI, Jotte RM, Gadgeel SM, Mita AC, Hart LL, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Pietanza MC. Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). ASCO Meeting Abstracts. 2014;32(15_suppl):7601. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7601. 228. Spunt SL, Million L, Anderson JR, Coffin CM, McCarville B, Randall RL, Parham D, Kao SC, Hayes-Jordan AA, Wolden SL, Terezakis SA, Black J, Laurie F, Kawashima E, Speights RA, Skapek S, Meyer WH, Hawkins DS, Pappo AS. Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children's Oncology Group study ARST0332. ASCO Meeting Abstracts. 2014;32(15_suppl):10008. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10008. 229. Stathis A, Maddocks KJ, Flinn I, Mejia A, Palomba ML, Zildjian S, Murphy M, Deckert J, Ruiz-Soto R, Freedman A. Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts. 2014;32(15_suppl):8526. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8526. 230. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, Burke MM, Ralabate AL, Rivera AL, Kronenberg SA, Agunwamba B, Feely W, Hong Q, Krishnan S, Gupta AK, Wolchok JD. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO Meeting Abstracts. 2014;32(15_suppl):LBA9003. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA9003. 231. Tan DS-W, Shaw AT, Mehra R, Felip E, Chow LQM, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, Liu G, Santoro A, Geraldes M, Boral A, Yovine AJ, Kim D-W. Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. ASCO Meeting Abstracts. 2014;32(15_suppl):8078. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8078. 232. Tap WD, Anthony SP, Chmielowski B, Staddon AP, Cohn AL, Shapiro G, Puzanov I, Kwak EL, Wagner AJ, Peterfy C, Hsu HH, Gee C, Lin PS, Tong S, Wainberg ZA. A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS). ASCO Meeting Abstracts. 2014;32(15_suppl):10503. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10503.



233. Tawbi HA-H, Chu E, Lin Y, Hyman DM, Goel S, Rudek MA, Dowlati A, LoRusso P, Mulkerin D, Chew HK, Kiesel B, Pollice L, Appleman LJ, Puhalla S, Stoller RG, Lee JJ, Ivy P, Beumer JH, NCI-Organ Dysfunction Working Group. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). ASCO Meeting Abstracts. 2014;32(15_suppl):2572. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2572. 234. Tempero MA, Cardin DB, Biankin A, Goldstein D, Moore M, O'Reilly EM, Philip PA, Riess H, Macarulla T, Yung L, Wei X, Lu B. APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS4162. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4162. 235. Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, Stuckey A, Rice L, Tewari KS, Aghajanian C. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). ASCO Meeting Abstracts. 2014;32(15_suppl):5546. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5546. 236. Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). ASCO Meeting Abstracts. 2014;32(15_suppl):e20669. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20669. 237. Touijer KA, Chen Y, Carver BS, Coleman JA, Laudone VP, Hullings M, Ehrlich SS, DeNunzio M, Reuter VE, Eastham JA, Danila DC, Slovin SF, Morris MJ, Chen Y, Scardino PT, Scher HI, Rathkopf DE. Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS5105. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS5105. 238. Traina TA, Kaufman PA, Cadoo KA, Hudis CA, Chang C, Berrak E, Song J, Cox D, Seidman AD. Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS670. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS670.



239. Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME, Steinberg JL, Trudeau ME, Hudis CA, Schmid P. A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS1144. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1144. 240. Voss MH, Adamo B, Heist RS, Gandhi L, Moulon C, Tanaka H, Ishii N, Vaslin A, Aoki Y, Nicolas-Metral V, Brienza S, Zanna C, Flaherty K, Tabernero J, Baselga J. First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15_suppl):TPS2629. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS2629. 241. Voss MH, Chen D, Marker M, Hamilton M, Kalfoglou C, Hsieh J, Knox JJ, Anak O, Motzer RJ. Identification and validation of predictive biomarkers (BM) for everolimus (EVE) in metastatic renal cell carcinoma: Analysis of 442 patients on RECORD-3. ASCO Meeting Abstracts. 2014;32(15_suppl):4531. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4531. 242. Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio as an independent predictor of disease-specific survival in resectable GE junction and gastric adenocarcinoma. ASCO Meeting Abstracts. 2014;32(15_suppl):4056. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4056. 243. Warren GW, Alberg A, Cummings KM, Dresler CM, Hanna NH, Ostroff JS, Marshall JR. The effect of current smoking on mortality in cancer patients. ASCO Meeting Abstracts. 2014;32(15_suppl):1580. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1580. 244. Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Rosenberg JE, Bajorin DF, Hansel DE, Al-Ahmadie H, Gordenin D, Stuart JM, Robertson G, Kucherlapati R, Laird PW, Mills GB, Kwiatkowski DJ, Lerner SP, representing The Cancer Genome Atlas Bladder Cancer Working Group. Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. ASCO Meeting Abstracts. 2014;32(15_suppl):4509. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4509. 245. Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander BM, Rinne ML, Colman H, Omuro AMP, DeAngelis LM, Gilbert MR, De Groot JF, Cloughesy TF, Chi AS, Lee EQ, Nayak L, Batchelor T, Chang SM, Prados M, Reardon DA, Ligon KL. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. ASCO Meeting Abstracts. 2014;32(15_suppl):2019. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2019.



246. Wiesenthal A, Moryl N, Glare PA. Opening the door of your patient's medicine cabinet: Unexpected outcomes of cancer pain management. ASCO Meeting Abstracts. 2014;32(15_suppl):e20629. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20629. 247. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Lin H, Gillenwater AM, Martin JW, Cohen EEW, Lingen MW, Boyle J, Shin DM, Vigneswaran N, Shinn N, Myers J, El-Naggar AK, Lippman SM. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). ASCO Meeting Abstracts. 2014;32(15_suppl):6007. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6007. 248. Won E, Ilson DH, Chou JF, Capanu M. Activity of gemcitabine/5-FU combination in refractory esophagogastric (EG) cancer. ASCO Meeting Abstracts. 2014;32(15_suppl):e15073. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15073. 249. Won E, Ilson DH, Herrera J, Janjigian YY, Ku GY, Rizk NP, Sarkaria IS, Rusch VW, Adusumili PS, Bains MS. Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer? ASCO Meeting Abstracts. 2014;32(15_suppl):4010. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4010. 250. Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon J, Sampson J, Kleinerman R. Risk of subsequent malignant neoplasms in long-term retinoblastoma survivors following chemotherapy and radiotherapy. ASCO Meeting Abstracts. 2014;32(15_suppl):10079. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10079. 251. Wright AA, Cronin A, Milne D, Bookman MA, Burger RA, Cristea MC, Griggs JJ, Levenback C, Niland JC, Weeks JC, O'Malley D. Effect of intraperitoneal chemotherapy on survival for ovarian cancer in clinical practice and frequency of use. ASCO Meeting Abstracts. 2014;32(15_suppl):5576. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5576. 252. Yen C-J, Daniele B, Kudo M, Merle P, Park J-W, Ross PJ, Peron J-M, Ebert O, Chan SL, Poon RTP, Colombo M, Okusaka T, Ryoo B-Y, Minguez B, Tanaka T, Ohtomo T, Rutman O, Chen Y-C, Lee R-m, Abou-Alfa GK. Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168). ASCO Meeting Abstracts. 2014;32(15_suppl):4102. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4102. 253. Younes A, Zinzani PL, Sehn LH, Johnson PWM, Gascoyne RD, Ahmadi T, Bellew KM, Vermeulen J, Zhuang SH, Sun S, Staudt LM, Wilson WH. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab,



cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS8615. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8615. 254. Yu HA, Hellmann MD, Sima CS, Busby N, Rodriguez K, Riely GJ, Kris MG. Stage at diagnosis as a prognostic marker for patients with KRAS-mutant metastatic lung adenocarcinomas. ASCO Meeting Abstracts. 2014;32(15_suppl):8111. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8111. 255. Yu KH, Sangar V, Ricigliano M, Hidalgo M, O'Reilly EM, Abou-Alfa GK, Lowery MA, Crotty JF, Gary K, Cooper B, Lapidus RG, Sadowska M. Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting. ASCO Meeting Abstracts. 2014;32(15_suppl):4130. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4130. 256. Zamarin D, Holmgaard RB, Subudhi SK, Park J-S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. ASCO Meeting Abstracts. 2014;32(15_suppl):3051. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3051. 257. Zauderer MG, Gucalp A, Epstein AS, Seidman AD, Caroline A, Granovsky S, Fu J, Keesing J, Lewis S, Co H, Petri J, Megerian M, Eggebraaten T, Bach P, Kris MG. Piloting IBM Watson Oncology within Memorial Sloan Kettering's regional network. ASCO Meeting Abstracts. 2014;32(15_suppl):e17653. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17653. 258. Zauderer MG, Rimner A, Rosenzweig K, Wu AJ-C, Yorke E, Sima CS, Bhattacharjee N, Patel Z, Gomez DR, Tsao AS, Rice DC, Mehran RJ, Adusumili PS, Rusch VW, Krug LM. A multicenter phase II toxicity study of lung-sparing intensity modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts. 2014;32(15_suppl):7581. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7581.


asco 2014 meeting abstracts - home | memorial sloan kettering … · 2016-08-18 · 18. barr pm, li...

Documents